These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8059672)

  • 1. Delineation of gliomas with various doses of MR contrast material.
    Yuh WT; Nguyen HD; Tali ET; Mayr NA; Fisher DJ; Atlas SW; Carvlin MC; Drayer BP; Pollei SR; Runge VM
    AJNR Am J Neuroradiol; 1994 May; 15(5):983-9. PubMed ID: 8059672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macroscopic tumor volume of malignant glioma determined by contrast-enhanced magnetic resonance imaging with and without magnetization transfer contrast.
    Hawighorst H; Schreiber W; Knopp MV; Essig M; Engenhart-Cabilic R; Brix G; van Kaick G
    Magn Reson Imaging; 1996; 14(10):1119-26. PubMed ID: 9065901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: value of administering a high dose of contrast material.
    Runge VM; Kirsch JE; Wells JW; Dunworth JN; Woolfolk CE
    AJR Am J Roentgenol; 1994 Feb; 162(2):431-5. PubMed ID: 8310940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-enhanced magnetic resonance imaging in a spinal epidural tumor model.
    Runge VM; Lee C; Iten AL; Williams NM
    Invest Radiol; 1997 Oct; 32(10):589-95. PubMed ID: 9342117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.
    Hamilton BE; Nesbit GM; Dosa E; Gahramanov S; Rooney B; Nesbit EG; Raines J; Neuwelt EA
    AJR Am J Roentgenol; 2011 Oct; 197(4):981-8. PubMed ID: 21940589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective enhancement of experimental rat brain tumors with Gd-TPPS.
    Bockhorst K; Els T; Hoehn-Berlage M
    J Magn Reson Imaging; 1994; 4(3):451-6. PubMed ID: 8061446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model.
    Robert P; Vives V; Grindel AL; Kremer S; Bierry G; Louin G; Ballet S; Corot C
    Radiology; 2020 Jan; 294(1):117-126. PubMed ID: 31660804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of cerebral perfusion by first-pass, dynamic, contrast-enhanced, steady-state free-precession MR imaging: an animal study.
    Runge VM; Kirsch JE; Wells JW; Woolfolk CE
    AJR Am J Roentgenol; 1993 Mar; 160(3):593-600. PubMed ID: 8430562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
    Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
    AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detectability of small liver metastases with gadolinium BOPTA.
    Runge VM; Lee C; Williams NM
    Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose gadoteridol in MR imaging of intracranial neoplasms.
    Runge VM; Kirsch JE; Burke VJ; Price AC; Nelson KL; Thomas GS; Dean BL; Lee C
    J Magn Reson Imaging; 1992; 2(1):9-18. PubMed ID: 1623287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging of an experimental model of intracranial metastatic disease. A study of lesion detectability.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1994 Dec; 29(12):1050-6. PubMed ID: 7721546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between contrast enhancement on fluid-attenuated inversion recovery MR sequences and signal intensity on T2-weighted MR images: visual evaluation of brain tumors.
    Kubota T; Yamada K; Kizu O; Hirota T; Ito H; Ishihara K; Nishimura T
    J Magn Reson Imaging; 2005 Jun; 21(6):694-700. PubMed ID: 15906343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
    Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
    Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.
    Yuh WT; Fisher DJ; Engelken JD; Greene GM; Sato Y; Ryals TJ; Crain MR; Ehrhardt JC
    Radiology; 1991 Aug; 180(2):485-91. PubMed ID: 2068317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates.
    Kamson DO; Juhász C; Buth A; Kupsky WJ; Barger GR; Chakraborty PK; Muzik O; Mittal S
    J Neurooncol; 2013 Mar; 112(1):121-32. PubMed ID: 23299463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging and histopathology of cerebral gliomas.
    Watanabe M; Tanaka R; Takeda N
    Neuroradiology; 1992; 34(6):463-9. PubMed ID: 1436452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Contrast-enhanced MR "magnetization transfer technique". Improved tumor contrast, delineation and visibility of intracranial malignant gliomas and metastases in radiosurgical treatment planning].
    Hawighorst H; Schreiber W; Debus J; Knopp MV; Engenhart-Cabillic R; Brix G; Essig M; van Kaick G
    Strahlenther Onkol; 1997 Dec; 173(12):684-92. PubMed ID: 9454354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
    Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
    Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.